Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

Corporate

29 December 2009 CSL Behring Awards Fourth Round of LEAD Grants

CSL Behring, a global leader in the plasma-protein biotherapies industry and a subsidiary of CSL Limited (ASX:CSL), has awarded four advocacy grants totaling $87,000 to patient organizations in the United States through the Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support grassroots advocacy efforts by organizations committed to helping people who use plasma-derived or recombinant therapies manage their health conditions. Since the LEAD program’s inception in 2008, CSL Behring has awarded more than $340,000 in four semi-annual grant cycles. The deadline for the fifth round of grant requests is April 30, 2010.

> Read More
06 October 2009 CSL Behring Solicits Proposals for LEAD Grants to Support Patient Advocacy Efforts

CSL Behring, a global leader in the plasma-protein biotherapeutics industry, is calling for grant requests through its Local Empowerment for Advocacy Development (LEAD) program. The LEAD program awards funds to United States patient organizations that assist people with rare diseases in advocating for continued access to health care and life-saving plasma protein therapies.

> Read More
28 July 2009 CSL Behring Awards Third Round of LEAD Grants Supporting Patient Organization Advocacy

CSL Behring, a global leader in the plasma-protein biotherapies industry, has awarded six advocacy grants totaling $100,000 to patient organizations in the United States through the Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support grassroots advocacy efforts by organizations that are committed to helping people who use plasma-derived and recombinant therapies to manage their health conditions. Since the LEAD program’s inception in 2008, CSL Behring has awarded more than $250,000 in three semi-annual grant cycles.

> Read More
08 June 2009 CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement

CSL Limited (ASX: CSL) and Talecris Biotherapeutics, Inc. announced today that they have mutually agreed to terminate their merger agreement, announced on August 12, 2008, under which CSL agreed to acquire Talecris for US$3.1 billion in cash.

> Read More
18 May 2009 ZLB Plasma Changes Name to CSL Plasma

ZLB Plasma has changed its name to CSL Plasma to align more closely with its parent company, CSL Limited. CSL Plasma is one of the world’s largest collectors of human plasma for use in manufacturing life-saving biotherapies. Headquartered in Boca Raton, FL, CSL Plasma operates collection centers throughout the United States and in Germany. It also operates state-of-the-art testing laboratories in Knoxville, TN and Goettingen, Germany, and logistics centers in Indianapolis, IN and Schwalmstadt, Germany.

> Read More
Page 3 of 6 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+